Review Article
Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
Table 2
Phase III trials of somatostatin analogs and molecular targeting therapy in advanced NETs.
| Tumor type and treatment regimen | Patients (number) | ORR (%) | Median PFS (months) | Median TTP (months) | Criteria |
| Pancreatic NETs | | | | | | Raymond et al. [71] | | | | | RECIST | Sunitinib | 86 | 9 | | 11.4 | | Placebo | 8 | 0 | | 5.5 | | Yao et al. [72] (RADIANT-3 study) | | | | | RECIST | Everolimus | 207 | | 11.0 | | | Placebo | 203 | | 4.6 | | | Small bowel NETs | | | | | | Rinke et al. [65] (PROMID study) | | | | | WHO | Octreotide LAR | 42 | 2 | | 14.3 | | Placebo | 43 | 2 | | 6.0 | | Pavel et al. [73] (RADIANT-2 study) | | | | | RECIST | Everolimus + octreotide LAR | 211 | | 16.4 | | | Placebo + octreotide LAR | 204 | | 11.3 | | | Small bowel and pancreatic NETs | | | | | | Caplin et al. [62] (CLARINET study) | | | | | RECIST | Lanreotide autogel | 101 | | Not achieved | | | Placebo | 103 | | 18.0 | | | Small bowel and lung NETs | | | | | | Yao et al. [74] (RADIANT-4 study) | | | | | RECIST | Everolimus | 205 | | 11.0 | | | Placebo | 97 | | 3.9 | | |
|
|
ORR, overall response rate; PFS, progression-free survival; TTP, time to progression; RECIST, Response Evaluation Criteria in Solid Tumors; LAR, long-acting release; WHO, World Health Organization tumor response criteria.
|